186 results on '"Jackson, David J."'
Search Results
2. Celebrating Polish American Identity
3. Eosinophilic asthma
4. Safety of eosinophil depletion
5. Introduction
6. Preserved antibody responses to COVID-19 vaccination and lower odds of developing COVID-19 in adults with severe asthma
7. MELTEMI and COLUMBA: 5-Year Comparative Safety Analysis of Benralizumab and Mepolizumab
8. Long-Term Effectiveness of Benralizumab in Eosinophilic Granulomatosis With Polyangiitis
9. Longitudinal patterns of intermittent oral corticosteroid use for asthma in the UK
10. Reply to “Exploring the long-term effects of biologic initiation in severe asthma: Insights from the International Severe Asthma Registry”
11. International variation in severe exacerbation rates in patients with severe asthma
12. Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study
13. Pioneering a paradigm shift in asthma management: remission as a treatment goal
14. Impact of pre-biologic impairment on meeting domain-specific biologic responder definitions in patients with severe asthma
15. Association Between T2-related Comorbidities and Effectiveness of Biologics in Severe Asthma
16. The Political Divergence of Ohio and Michigan
17. The RNA binding proteins ZFP36L1 and ZFP36L2 are dysregulated in airway epithelium in human and a murine model of asthma
18. Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry
19. IL-33-induced neutrophilic inflammation and NETosis underlie rhinovirus-triggered exacerbations of asthma
20. Greenhouse Gas Emissions from Respiratory Treatments: Results from the SABA CARBON International Study
21. Clinical remission following biologic initiation in severe asthma: results of the International Severe Asthma Registry (ISAR)
22. Real-world associations between outcomes and biomarkers in severe asthma patients treated with biologics
23. Real world biologic treatment response in severe asthma: an analysis of the International Severe Asthma Registry (ISAR)
24. Late Breaking Abstract - SHAMAL: reduction of maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab: a randomised phase 4 study
25. Asthma outcomes in patients (pts) with severe eosinophilic asthma (SEA), with and without comorbid chronic rhinosinusitis with nasal polyps (NP), treated with benralizumab in the real-world XALOC-1 study
26. The proportion of patients achieving low biomarker levels with tezepelumab treatment in the phase 3 NAVIGATOR study
27. Characteristics associated with clinical remission in patients with severe asthma who initiate biologics
28. The impact of steroid-sparing biologic therapies on weight loss in obese individuals with severe eosinophilic asthma
29. Blood transcriptomic signature in type-2 biomarker-low severe asthma and asthma control
30. Impact of Initiating Biologics in Patients With Severe Asthma on Long-Term Oral Corticosteroids or Frequent Rescue Steroids (GLITTER): Data From the International Severe Asthma Registry
31. A Randomized Trial of a Composite T2-Biomarker Strategy Adjusting Corticosteroid Treatment in Severe Asthma: A Post Hoc Analysis by Sex
32. Comparative effectiveness of anti‐IL5 and anti‐IgE biologic classes in patients with severe asthma eligible for both
33. Application of an algorithm to analyze patterns of intermittent oral corticosteroid use in asthma
34. Dupilumab Efficacy in Patients with Uncontrolled Moderate-to-Severe Type 2 Asthma Regardless of Perennial Aeroallergen Sensitization
35. Use of digital measurement of medication adherence and lung function to guide the management of uncontrolled asthma (INCA Sun): a multicentre, single-blinded, randomised clinical trial
36. Observational UK cohort study to describe intermittent oral corticosteroid prescribing patterns and their association with adverse outcomes in asthma
37. IL-33-induced neutrophilic inflammation and NETosis underlie rhinovirus-triggered exacerbations of asthma
38. A Renewed Charter: Key Principles to Improve Patient Care in Severe Asthma
39. Characterization of Patients in the International Severe Asthma Registry with High Steroid Exposure Who Did or Did Not Initiate Biologic Therapy
40. Living without eosinophils: evidence from mouse and man
41. In vivo bronchial epithelial interferon responses are augmented in asthma on day 4 following experimental rhinovirus infection
42. Dupilumab Efficacy in Steroid-Dependent Severe Asthma by Baseline Oral Corticosteroid Dose
43. Benefits of specialist severe asthma management: demographic and geographic disparities
44. Improvement in Lung Function with Dupilumab Does Not Predict Its Effects on Reducing Asthma Exacerbation
45. Benralizumab Effectiveness in Severe Asthma Is Independent of Previous Biologic Use
46. Assessing adherence to inhaled therapies in asthma and the emergence of electronic monitoring devices
47. COVID‐19 in the absence of eosinophils: The outcome of confirmed SARS‐CoV‐2 infection whilst on treatment with benralizumab
48. Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma
49. Improving Care in Eosinophil-Associated Diseases: A Charter
50. Disease-modifying anti-asthmatic drugs
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.